近日，国家药品监督管理局正式批准佰仁医疗旗下胶原蛋白植入剂的注册申请。该产品是国内首个基于牛源Ⅰ型胶原蛋白、用于软组织填充的三类医疗器械，标志着我国在高端生物材料领域取得重要突破。佰仁医疗胶原蛋白植入剂采用高纯度、低免疫原性的胶原蛋白原料，经过严格工艺处理，具有良好的生物相容性和可降解性，适用于面部轮廓修饰、皱纹填充等医美场景。与传统玻尿酸类产品相比，该胶原蛋白植入剂不仅可提供即时填充效果，还能促进自身胶原再生，实现更自然、持久的修复效果。此次获批不仅丰富了国内医美市场的产品选择，也体现了监管部门对创新生物材料临床转化的支持。未来，佰仁医疗计划围绕胶原蛋白平台拓展更多适应症，推动其在创面修复、组织工程等领域的应用，进一步提升国产高端医疗器械的国际竞争力。
Recently, China’s National Medical Products Administration (NMPA) officially approved the registration of BenRen Medical’s collagen implant. This product is the first Class III medical device in China based on bovine type I collagen for soft tissue augmentation, marking a significant breakthrough in the field of advanced biomaterials. The implant utilizes high-purity, low-immunogenicity collagen processed through stringent manufacturing protocols, offering excellent biocompatibility and biodegradability. It is indicated for aesthetic applications such as facial contouring and wrinkle correction. Compared to traditional hyaluronic acid fillers, this collagen implant not only provides immediate volumizing effects but also stimulates the body’s natural collagen production, resulting in more natural and longer-lasting outcomes. The approval expands the range of options available in China’s aesthetic medicine market and reflects regulatory support for the clinical translation of innovative biomaterials. Looking ahead, BenRen Medical plans to leverage its collagen platform to explore additional indications, including wound healing and tissue engineering, further enhancing the global competitiveness of domestically developed high-end medical devices.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/2332.html